Onkologie. 2009:3(2):106-110

Bisphosphonates in the treatment of metastatic bone disease

MUDr. Zdeněk Mechl, CSc, prof. MUDr. Rom Kostřica CSc
Klinika ORL a chirurgie hlavy a krku, FN u sv. Anny v Brně

Patients with bone metastases from breast, prostate, lung cancer and other solid tumors may suffer from considerable morbidity and

develop debilitating skeletal-related events (SREs). Bisphosphonates are the primary intervention for patients with metastatic disease

at risk for SREs. Bisphosphonates maintain bone health in patients with breast or prostate who experience bone loss from hormoneablative

therapies. Recent preclinical and preliminary clinical evidence suggest that bisphopshonates also have antitumor activity that

may result in clinical benefits beyond the maintenance of bone health.

Keywords: bone metastases, bisphosphonates, antitumor activity.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mechl Z, Kostřica R. Bisphosphonates in the treatment of metastatic bone disease. Onkologie. 2009;3(2):106-110.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Ševčík P, Vorlíček J, et al. Kostní nádorová choroba. Grada 2005.
    2. Clézardin P. Pathophysiology of bone metastases. ZENITH Meeting 2009.
    3. Kolombo I. Teorie vzniku kostních metastáz. EUNI 2008.
    4. Aapro M, Abrahamson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol. 2008; 10: 420-433. Go to original source... Go to PubMed...
    5. Mystakidou K, Katsouda P, Parpa E, et al. Randomized opel label, prospective study on the effect of zoledronc acid on the prevention of bone metastases in patients wtith recurrent solid tumors that did not present with bone metastase at baseline. Medical Oncology 2005; 2: 198-201. Go to original source... Go to PubMed...
    6. Rack B, Schindlbeck C, Strobl B, et al. Efficacy of zoledronat in treating persisting isolated tumors cells in bone marrow in patients with breast cancer. A phase in pilot study. Dtsch med Wochenschr 2008; 133: 285-285. Go to original source... Go to PubMed...
    7. Lin A, Park JW, Scoty J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. ASCO 2008: Abst 559. Go to original source...
    8. Aft R, Watson M, Ylagen L, et al. Effect of zoledronic acid on bone marrow micrometastaes in women under chemotherapy for breast cancer. ASCO 2008; Abst 1921.
    9. Gnant M. Improving patient outcomes with bisphoshonate therapy in the adjuvant setting. ZENITH Meeting 2009.
    10. Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Sem Oncology 2007; 34 (Suppl 4): 11-16. Go to original source... Go to PubMed...
    11. Saad F, et al. Cancer. 2007; 110(8): 1860-1867.
    12. Lipton A, et al. J Nat Cancer Inst 2008; 14(20): 6690-6696. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.